- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA granted Fast Track designation to PRX012, marking a collaboration between Prothena (Ireland) and Roche for prasinezumab aimed at Parkinson's disease.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Fast Track designation to PRX012, marking a collaboration between Prothena (Ireland) and Roche for prasinezumab aimed at Parkinson's disease.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
-
Prothena (Ireland)
company in Dublin, Ireland
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksProthena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? A month has gone by since the last earnings report for Prothena (PRTA). Shares have added about 17.6% in that time frame, outperf